Is Atrium Therapeutics (RNA) stock Halal?

Atrium Therapeutics is a biotechnology company focused on the development of innovative therapies for unmet medical needs. The primary aim of Avidity is to harness its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform to create transformative healthcare solutions. This platform combines antibodies and oligonucleotides to precisely target and deliver therapeutic payloads to specific diseased cells, potentially advancing treatments for a range of genetic disorders. Before any of that matters to a Muslim investor, one question comes first: is Atrium Therapeutics stock Halal?

Is Atrium Therapeutics Shariah compliant?

No. In the October 2026 screening Atrium Therapeutics (RNA) does not pass AAOIFI screening: it fails the non-permissible income and interest-bearing investments screens. The Shariah case on a technology company like Atrium Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Atrium Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: Atrium Therapeutics currently fails the non-permissible income and interest-bearing investments screens, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Atrium Therapeutics' income Halal?

No. Atrium Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does Atrium Therapeutics meet AAOIFI's debt and investment ratio requirements?

Not in full. Interest bearing investments currently exceed the 30% cap, measured against a market capitalisation of $142M (market data as of 1 October 2026), while the other ratio stays within it. One breach is enough to fail the screening; the ratios are reassessed monthly under our Shariah Supervisory Board.

Why do other halal screeners show a different verdict for Atrium Therapeutics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing